Observational studyAntimicrobial agents and chemotherapy2019
Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Abstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Triple Versus Double Therapy for the Treatment of Severe Infections Caused by Carbapenem-Resistant Enterobacteriaceae: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China.BMC infectious diseases · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistantMicrobiology spectrum · 2026Article
- Genomic epidemiology of carbapenemase-producingMicrobial cell (Graz, Austria) · 2026Article
- Clinical outcomes and treatment effectiveness in patients with carbapenem-resistant Enterobacterales infections: a multicenter retrospective cohort study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Risk Factor Analysis of CRE Infections at Different Anatomical Sites in ICU Patients.Antibiotics (Basel, Switzerland) · 2025Article
- Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025Article
- Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.BMC infectious diseases · 2025Article
- The antimicrobial and antibiofilm effects of gentamicin, imipenem, and fucoidan combinations against dual-species biofilms of Staphylococcus aureus and Acinetobacter baumannii isolated from diabetic foot ulcers.Annals of clinical microbiology and antimicrobials · 2024Article
- Clinical and genomic characteristics of IMP-producingAntimicrobial agents and chemotherapy · 2024Article
- Clinical success of anti-infective combination therapy compare to monotherapy in patients with carbapenem-resistant Pseudomonas aeruginosa infection: a 10-years retrospective study.BMC infectious diseases · 2024Article
- Molecular epidemiology, risk factors, and outcomes of carbapenem-resistantFrontiers in microbiology · 2023Article
- Evaluation of Tigecycline Utilization and Trends in Antibacterial Resistance from 2018 to 2021 in a Comprehensive Teaching Hospital in China.Infection and drug resistance · 2023Article
- Rapid Identification of Carbapenemase-ProducingInfection and drug resistance · 2023Article
- Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan.BMC infectious diseases · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Differences in the Distribution of Species, Carbapenemases, Sequence Types, Antimicrobial Heteroresistance and Mortality Rates Between Pediatric and Adult Carbapenemase-ProducingFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Xiaojuan Wang *Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Qi Wang *Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Bin CaoDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Shijun SunDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Yawei ZhangDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Bing GuDepartment of Clinical Laboratory, Medical Technology Institute of Xuzhou Medical University, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Binbin LiDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Kang LiaoDepartment of Clinical Laboratory, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Feng ZhaoDepartment of Infectious Diseases, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Liang JinDepartment of Clinical Laboratory, First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.
Chunmei JinDepartment of Clinical Laboratory, Yanbian University Hospital, Yanji, Jilin, China.
Chunxia YangDepartment of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Fengyan PeiDepartment of Clinical Microbiology, Jinan Central Hospital, Jinan, Shandong, China.
Zhijie ZhangDepartment of Clinical Microbiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Hui WangDepartment of Clinical Laboratory, Peking University People's Hospital, Beijing, China whuibj@163.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data for a total of 164 bloodstream infection cases due to carbapenem-resistant
Indexed as
AdultAgedAnti-Bacterial AgentsBacteremiaBacterial Proteinsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeChinaDrug Therapy, CombinationEnterobacteriaceae InfectionsFemaleHospital MortalityHumansInappropriate PrescribingKlebsiella pneumoniaeMaleAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase KPC-2, Klebsiella pneumoniaebeta-LactamasescarbapenemaseMeropenemTigecyclinebacteremiacarbapenem-resistant Enterobacteriaceaecombination therapyin-hospital mortalitymonotherapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.